Skip to main content

Table 2 Type-specific high-risk HPV prevalence and incidence among HIV-negative high-risk women with normal cytology, Kigali, Rwanda

From: The epidemiology of human papillomavirus infection in HIV-positive and HIV-negative high-risk women in Kigali, Rwanda

  Prevalence* Incidence†
  No at risk No cases Prevalence proportion % (95% CI) No at risk No cases Incidence proportion % (95% CI)
Any HR 349 105 31 (26-36) 296 82 28 (23-33)
Alpha 9 (HPV-16-related types)
16 349 19 5 (3-8) 282 12 4 (2-7)
31 349 11 3 (1-5) 286 10 3 (1-6)
33 349 7 2 (1-4) 289 8 3 (1-5)
35 349 12 4 (2-6) 285 4 1 (0-3)
52 349 15 4 (2-6) 287 16 6 (3-8)
58 349 14 4 (2-6) 284 10 4 (1-6)
Alpha 7 (HPV-18 related types)
18 349 11 3 (1-5) 289 13 4 (2-7)
39 349 8 2 (1-4) 290 5 2 (0-3)
45 349 17 5 (3-7) 281 7 2 (1-4)
59 349 11 3 (1-5) 286 12 4 (2-7)
68 349 13 4 (2-6) 286 7 2 (1-4)
Other types
51 349 12 4 (2-6) 287 11 4 (2-6)
56 349 8 2 (1-4) 290 8 3 (1-5)
73 349 5 1 (0-3) 291 3 1 (0-2)
82 349 1 0 (0-1) 295 3 1 (0-2)
Iso39 349 1 0 (0-1) 295 1 0 (0-1)
  1. *Type-specific prevalence at M6 visit. Population at risk includes HIV-negative women with/without HR-HPV co-infection with other types than the type at interest; †Type-specific incidence. Population at risk includes HIV-negative women with/without HR-HPV infection with other types than the type at interest.; 320 women had HPV results at M6 and Year 2; 15 were excluded because of abnormal cytology results; another 9 because HIV seroconversion; mean interval incidence 16.6 months (SD 1.8)